Rivaroxaban FDA approved for Afib

The FDA announced today that rivaroxaban has been approved for the prevention of stroke related to Afib. Approval was based on the ROCKET-AF trial, which found it was non-inferior to warfarin in stroke prevention in Afib. It is dosed 20mg a day, with no monitoring required. (abstract)

Danielle Scheurer

Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.

Leave a Comment